Interleukin (IL)-4 Antibody Market Report 2026

The interleukin (il)-4 antibody market size has grown strongly in recent years. It will grow from $2.32 billion in 2025 to $2.53 billion in 2026 at a compound annual growth rate (CAGR) of 8.8%. The growth in the historic period can be attributed to growth in allergy and asthma research, increasing use of cytokine assays, expansion of academic immunology studies, rising availability of monoclonal antibody platforms, growth of biomedical research funding.

The interleukin (il)-4 antibody market size is expected to see strong growth in the next few years. It will grow to $3.5 billion in 2030 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to increasing demand for precision immunomodulators, expansion of autoimmune disease research, rising investments in biologics development, growing focus on translational research applications, increasing adoption of advanced immunoassays. Major trends in the forecast period include increasing use of il-4 antibodies in immunology research, rising development of targeted immunotherapies, growing adoption of high-specificity monoclonal antibodies, expansion of cytokine profiling applications, enhanced focus on antibody validation standards.

The growing prevalence of allergic diseases is expected to drive the expansion of the interleukin (IL)-4 antibody market in the coming years. Allergic diseases are immune system conditions in which the body reacts excessively to normally harmless substances such as pollen, dust, or certain foods, resulting in symptoms including inflammation, itching, and breathing difficulties. The increase in allergic disease prevalence is largely attributed to urbanization and environmental changes, which heighten exposure to pollutants and allergens that trigger immune hypersensitivity. Interleukin (IL)-4 antibodies help manage allergic diseases by selectively targeting IL-4 signaling pathways, making them effective in reducing immune overreactions. They help relieve symptoms such as inflammation, itching, and respiratory discomfort, thereby improving patient comfort and overall quality of life. For example, in February 2025, the National Asthma Council Australia, a not-for-profit organization based in Australia, reported a total of 474 asthma-related deaths, reflecting a slight year-on-year increase of 0.2% from 473 deaths in 2022, with females accounting for 68.6% and males for 31.4% of cases. Consequently, the rising prevalence of allergic diseases is fueling growth in the interleukin (IL)-4 antibody market.

Leading companies in the interleukin (IL)-4 antibody market are concentrating on the development of innovative therapies, including next-generation bispecific antibodies, to address tumor resistance and enhance anti-cancer efficacy. Next-generation bispecific antibodies are engineered to bind two different antigens or epitopes simultaneously, improving therapeutic outcomes by modulating multiple biological pathways at once, increasing specificity, and potentially reducing side effects compared to single-target antibodies. For instance, in February 2025, Akeso Inc., a China-based biopharmaceutical company, received Investigational New Drug (IND) approval from the China National Medical Products Administration for AK139, a bispecific antibody. AK139 simultaneously targets interleukin-4 receptor alpha and the ST2 receptor, blocking both the interleukin-4/interleukin-13 and interleukin-33 pathways. This dual-targeting approach is designed to reduce inflammatory cytokine release and tissue infiltration more effectively, potentially delivering stronger and longer-lasting control of type-2 and related inflammatory responses in respiratory and dermatological conditions.

In June 2025, Bio-Thera Solutions Ltd., a China-based biopharmaceutical company, entered into a partnership with SteinCares S.A. to commercialize a proposed dupilumab biosimilar for the treatment of chronic inflammatory diseases across Latin America for an undisclosed value. Through this collaboration, Bio-Thera Solutions will contribute its biologics development and supply expertise, while SteinCares will oversee regulatory registration and commercialization activities throughout the region. SteinCares S.A., a US-based specialty healthcare company, focuses on IL-4 antibody therapies and related research products.

Major companies operating in the interleukin (il)-4 antibody market are Sanofi S.A., Thermo Fisher Scientific Inc., Merck KGaA, Becton Dickinson and Company, Regeneron Pharmaceuticals Inc., Bio-Rad Laboratories Inc., GeneTex Inc., Miltenyi Biotec B.V. & Co. KG, GenScript Biotech Corporation, Cell Signaling Technology Inc., Elabscience Biotechnology Inc., RayBiotech Life Inc., Santa Cruz Biotechnology Inc., Atlas Antibodies AB, Creative Biolabs Inc., Abnova (Taiwan) Corporation, Wuhan Fine Biotech Co. Ltd., United States Biological LLC, NSJ Bioreagents, Boster Biological Technology Co. Ltd.

North America was the largest region in the interleukin (IL)-4 antibody market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the interleukin (il)-4 antibody market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the interleukin (il)-4 antibody market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the interleukin (IL)-4 antibody market by increasing costs of imported raw biological materials, laboratory reagents, analytical instruments, and cold-chain logistics services. Research institutions and biopharmaceutical companies in North America and Europe are most affected due to reliance on cross-border sourcing of specialized antibodies. These tariffs are increasing procurement costs and extending development timelines. However, they are also encouraging localized antibody production, regional biomanufacturing investments, and stronger domestic research supply ecosystems.

The interleukin (il)-4 antibody market research report is one of a series of new reports that provides interleukin (il)-4 antibody market statistics, including interleukin (il)-4 antibody industry global market size, regional shares, competitors with a interleukin (il)-4 antibody market share, detailed interleukin (il)-4 antibody market segments, market trends and opportunities, and any further data you may need to thrive in the interleukin (il)-4 antibody industry. This interleukin (il)-4 antibody market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Interleukin (IL)-4 antibody is a laboratory-generated antibody that specifically targets IL-4, a cytokine involved in immune system regulation, particularly in driving Th2 cell differentiation and antibody production. It is used to detect, measure, or neutralize IL-4 in research or therapeutic settings, supporting the study or modulation of immune responses in conditions such as allergies, asthma, and autoimmune diseases.

The main types of interleukin (IL)-4 antibody include monoclonal antibodies and polyclonal antibodies. Monoclonal antibodies are highly specific immunoglobulins produced from a single B-cell clone that recognize a single epitope on interleukin (IL)-4 or its receptor. They are generated using hybridoma or recombinant expression systems and can be engineered for isotype, affinity, and effector function to ensure consistent performance in research and clinical workflows. Applications include enzyme-linked immunosorbent assay, immunohistochemistry (frozen), immunohistochemistry (paraffin), western blot, and others, and are used by end-users such as pharmaceutical and biotechnology companies, academic and research institutions, and contract research organizations (CROs).

The interleukin (IL)-4 antibody market also includes sales of recombinant interleukin (IL)-4 neutralizing antibodies, bispecific interleukin (IL)-4 antibodies, biosimilar interleukin (IL)-4 antibodies, antibody conjugates, assay kits, and related immunoassay reagents. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the antibodies, whether to other entities (including downstream manufacturers, wholesalers, distributors, and healthcare providers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.